CHRNA7 and triple-A syndrome: Furthermore, Hashimoto et al. found that a selective α7nAChRs agonist attenuates atherogenesis and AAA formation in ApoE−/− mice, supporting the anti-inflammatory capabilities of α7nAChRs [52].